Daily Signals
2758 companies scored · Total · absolute moveSwitch to Alpha · 30D 90D
Distribution of the day's forecasts
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
296 companies
Sorted by market cap ↓ · forecast rankings are part of the paid plans
| Ticker | Rating | 90D | Δ | |
|---|---|---|---|---|
| IMRXImmuneering Corp | Unlock rating and forecasts | |||
| SABSSAB Biotherapeutics, Inc. | +2.89% | · | ||
| SIGASIGA TECHNOLOGIES INC | +2.73% | · | ||
| NATRNATURES SUNSHINE PRODUCTS INC | Unlock rating and forecasts | |||
| BIOABioAge Labs, Inc. | Unlock rating and forecasts | |||
| LXEOLexeo Therapeutics, Inc. | Unlock rating and forecasts | |||
| FATEFATE THERAPEUTICS INC | Unlock rating and forecasts | |||
| GLSIGreenwich LifeSciences, Inc. | Unlock rating and forecasts | |||
| KROSKeros Therapeutics, Inc. | +3.03% | · | ||
| PLXProtalix BioTherapeutics, Inc. | Unlock rating and forecasts | |||
| ALECAlector, Inc. | Unlock rating and forecasts | |||
| ZNTLZentalis Pharmaceuticals, Inc. | Unlock rating and forecasts | |||
| NAGENiagen Bioscience, Inc. | +2.66% | · | ||
| RNACCartesian Therapeutics, Inc. | Unlock rating and forecasts | |||
| AKBAAkebia Therapeutics, Inc. | Unlock rating and forecasts | |||
| CGENCOMPUGEN LTD | +2.97% | · | ||
| IVVDInvivyd, Inc. | Unlock rating and forecasts | |||
| STROSUTRO BIOPHARMA, INC. | Unlock rating and forecasts | |||
| PEPGPepGen Inc. | Unlock rating and forecasts | |||
| ADCTADC Therapeutics SA | Unlock rating and forecasts | |||
| ACOGAlpha Cognition Inc. | +3.36% | ▼ 1 | ||
| ORMPORAMED PHARMACEUTICALS INC. | Unlock rating and forecasts | |||
| CMPXCompass Therapeutics, Inc. | Unlock rating and forecasts | |||
| CHRSCoherus Oncology, Inc. | Unlock rating and forecasts | |||
| MDWDMediWound Ltd. | +1.95% | ▲ 1 | ||
| UPBUpstream Bio, Inc. | Unlock rating and forecasts | |||
| NBPNovaBridge Biosciences | +3.01% | · | ||
| MOLNMOLECULAR PARTNERS AG | Unlock rating and forecasts | |||
| MSLESatellos Bioscience Inc. | +2.35% | · | ||
| DERMJourney Medical Corp | Unlock rating and forecasts | |||
| IPHAInnate Pharma SA | +2.53% | ▼ 1 | ||
| NKTXNkarta, Inc. | Unlock rating and forecasts | |||
| ORGOOrganogenesis Holdings Inc. | Unlock rating and forecasts | |||
| ANTXAN2 Therapeutics, Inc. | Unlock rating and forecasts | |||
| KRROKorro Bio, Inc. | Unlock rating and forecasts | |||
| ARMPArmata Pharmaceuticals, Inc. | Unlock rating and forecasts | |||
| ABOSAcumen Pharmaceuticals, Inc. | Unlock rating and forecasts | |||
| HUMAHumacyte, Inc. | Unlock rating and forecasts | |||
| OTLKOutlook Therapeutics, Inc. | Unlock rating and forecasts | |||
| VYGRVoyager Therapeutics, Inc. | Unlock rating and forecasts | |||
| NERVMinerva Neurosciences, Inc. | Unlock rating and forecasts | |||
| ENGNenGene Therapeutics Inc. | Unlock rating and forecasts | |||
| FHTXFoghorn Therapeutics Inc. | Unlock rating and forecasts | |||
| HURATuHURA Biosciences, Inc./NV | Unlock rating and forecasts | |||
| LENZLENZ Therapeutics, Inc. | Unlock rating and forecasts | |||
| INOINOVIO PHARMACEUTICALS, INC. | Unlock rating and forecasts | |||
By sector
Median 90D forecast per sector. Click to filter.
Rating changes
Unlock the full ranking
Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.
See plans Create a free accountRatings are relative: the forecasts of the latest complete daily run (2026-10-16) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected absolute price move over the horizon, market included. This is the number a price target is built from. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.